Segment Description: Dale N Gerding, MD, research physician, Edward Hines Jr. VA Hospital, provides insight about prevention options for C diff that are expected in the future.
Interview transcript: (modified slightly for readability):
“The[re are a few] prevention and treatment options, that are coming, we hope, in the future. For prevention—vaccines. Vaccines are currently—at least 1 of them—in phase 3 trials. One recently had its phase 3 trial stopped, which is disappointing, but that’s one possibility. The use of monoclonal antibody is a passive immune strategy that will likely help prevent recurrent C diff.
And then there are a number of strategies that are manipulating the microbiome that potentially, in the future, could be used as preventative strategies. One of those is the use of non-toxigenic C diff, which could colonize patients and prevent them from getting C diff in the future, and this is a short-term preventative strategy that should be effective for 1 to 2 months.”
To stay informed on the latest in infectious disease news and developments, please sign upfor our weekly newsletter.
Big advances in treatment can't make up for an inability to stop new infections, which number 5,000 per day worldwide.
Contagion® is a fully integrated news resource covering all areas of infectious disease. Through our website, quarterly journal, email newsletters, social media outlets, and Outbreak Monitor we provide practitioners and specialists with disease-specific information designed to improve patient outcomes and assist with the identification, diagnosis, treatment, and prevention of infectious diseases. Our mission is to assure that the healthcare community and public have the knowledge to make more informed choices and have a positive impact on patient outcomes.
2 Clarke Drive
Cranbury, NJ 08512